Florida Biologix spins off from University of Florida


Florida Biologix, a contract development and manufacturing organization focused on complex biological products, has been spun off from the University of Florida to FB2 Services Inc., a newly formed entity that will continue to operate as Florida Biologix.

FB2 is backed by an investment from Ampersand Capital Partners a Massachusetts-based private equity firm with extensive experience in the contract manufacturing of complex biologics. Ampersand’s investment will be used to further expand the company’s manufacturing capabilities in the areas of gene and cell therapies.

Under the deal FB2/Florida Biologix  will continue to manufacture complex biopharmaceutical products in the existing Progress Park facility and lease UF facilities on Innovation Drive in Alachua